In HCC, bromodomain and PHD finger containing-1 (BRPF1) induce the activation of oncogenes by stimulating gene promoter H3K14 acetylation, and BRPF1-targeted inhibitor GSK5959 demonstrates a promising capacity to ameliorate tumor progression in murine models of HCC [202]. This evidence concerns the gene BRPF1 and hepatocellular carcinoma.